COVID-19 Update: See the latest on our visitor policy here. Learn More
An Open-label, Single-arm, Multicohort, Phase 2 Study to Assess the Efficacy and Safety of Tabelecleucel in Subjects with Epstein-Barr Virus-associated Diseases
The purpose of this study is to assess the efficacy and safety of tabelecleucel in participants with Epstein-Barr virus (EBV) associated diseases.
Primary: To determine the clinical benefit of tabelecleucel in subjects with EBV-associated diseases as measured by ORR. Secondary: To evaluate additional clinically relevant outcomes in EBV-associated diseases treated with tabelecleucel. Safety: To characterize the safety profile of tabelecleucel in these patient populations. Exploratory: To assess quality of life using PROs To characterize the expansion and persistence of tabelecleucel and to correlate cellular kinetics of tabelecleucel with clinical benefit and safety. To characterize
Back to top
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate button below. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.